{
    "info": {
        "nct_id": "NCT04879940",
        "official_title": "Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization in Patients With Localized Prostate Carcinoma and Obstructive Lower Urinary Tract Symptoms",
        "inclusion_criteria": "* Histologically or cytologically confirmed prostate adenocarcinoma in the very low or low or favorable intermediate risk risk stratification groups (i.e. Gleason Grade groups 1 and 2) who are eligible for and who select XRT as their cancer management method.\n* Ability to receive prostatic artery embolization within 6-12 weeks of definitive radiation therapy.\n* Ability to understand and the willingness to sign a written informed consent document\n* Prostate larger than 60 grams but less than 150 grams, as assessed by imaging scans\n* American Urologic Association (AUA) or International Prostate Symptom Score (IPSS) Score ≥ 15\n* Normal organ and marrow function as defined in protocol\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 50 Years",
        "exclusion_criteria": "* Patients with Gleason Grade Group 1 or 2 PCa who select active surveillance as their cancer management method.\n* Receiving androgen deprivation therapy (ADT)\n* Patients with unfavorable intermediate (Gleason Grade Group 3) or high risk localized PCa (Gleason Grade Groups 4 and 5)\n* Receiving any investigational agents for the explicit purpose of prostatic size reduction\n* Inability to receive prostatic artery embolization (PAE) within 6-12 weeks of definitive radiation therapy\n* Active urinary tract infection (UTI)\n* History of severe allergic reaction to intravenous contrast media (iodinated and gadolinium- based) or any agents used during the PAE; patient cannot be medicated against allergic reaction prior to PAE.\n* Active cystolithiasis or prostatitis\n* Inability to have multi-parametric magnetic resonance imaging (mpMRI)\n* Prior transurethral resection of the prostate (TURP) within 2 years\n* Prostate size greater than or equal to150 grams\n* Vulnerable subjects (e.g., inmates and developmentally delayed adults) who are subjects for whom the study may be unsafe or whose rights may be violated with enrollment.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Histologically or cytologically confirmed prostate adenocarcinoma in the very low or low or favorable intermediate risk risk stratification groups (i.e. Gleason Grade groups 1 and 2) who are eligible for and who select XRT as their cancer management method.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed prostate adenocarcinoma",
                    "criterion": "prostate adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "very low or low or favorable intermediate risk risk stratification groups (i.e. Gleason Grade groups 1 and 2)",
                    "criterion": "risk stratification group",
                    "requirements": [
                        {
                            "requirement_type": "risk group",
                            "expected_value": [
                                "very low",
                                "low",
                                "favorable intermediate"
                            ]
                        },
                        {
                            "requirement_type": "Gleason Grade group",
                            "expected_value": [
                                "1",
                                "2"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "eligible for and who select XRT as their cancer management method",
                    "criterion": "XRT as cancer management method",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "selection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and the willingness to sign a written informed consent document",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prostate larger than 60 grams but less than 150 grams, as assessed by imaging scans",
            "criterions": [
                {
                    "exact_snippets": "Prostate larger than 60 grams but less than 150 grams, as assessed by imaging scans",
                    "criterion": "prostate size",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 60,
                                        "unit": "grams"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 150,
                                        "unit": "grams"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* American Urologic Association (AUA) or International Prostate Symptom Score (IPSS) Score ≥ 15",
            "criterions": [
                {
                    "exact_snippets": "American Urologic Association (AUA) or International Prostate Symptom Score (IPSS) Score ≥ 15",
                    "criterion": "AUA or IPSS score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Normal organ and marrow function as defined in protocol",
            "criterions": [
                {
                    "exact_snippets": "Normal organ and marrow function as defined in protocol",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    ]
                },
                {
                    "exact_snippets": "Normal organ and marrow function as defined in protocol",
                    "criterion": "marrow function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to receive prostatic artery embolization within 6-12 weeks of definitive radiation therapy.",
            "criterions": [
                {
                    "exact_snippets": "Ability to receive prostatic artery embolization",
                    "criterion": "prostatic artery embolization",
                    "requirements": [
                        {
                            "requirement_type": "ability to receive",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 6-12 weeks of definitive radiation therapy",
                    "criterion": "timing of prostatic artery embolization relative to definitive radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 50 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 50 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Receiving any investigational agents for the explicit purpose of prostatic size reduction",
            "criterions": [
                {
                    "exact_snippets": "Receiving any investigational agents for the explicit purpose of prostatic size reduction",
                    "criterion": "receipt of investigational agents for prostatic size reduction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to have multi-parametric magnetic resonance imaging (mpMRI)",
            "criterions": [
                {
                    "exact_snippets": "Inability to have multi-parametric magnetic resonance imaging (mpMRI)",
                    "criterion": "multi-parametric magnetic resonance imaging (mpMRI)",
                    "requirements": [
                        {
                            "requirement_type": "ability to undergo procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receiving androgen deprivation therapy (ADT)",
            "criterions": [
                {
                    "exact_snippets": "Receiving androgen deprivation therapy (ADT)",
                    "criterion": "androgen deprivation therapy (ADT)",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with unfavorable intermediate (Gleason Grade Group 3) or high risk localized PCa (Gleason Grade Groups 4 and 5)",
            "criterions": [
                {
                    "exact_snippets": "unfavorable intermediate (Gleason Grade Group 3)",
                    "criterion": "Gleason Grade Group",
                    "requirements": [
                        {
                            "requirement_type": "grade group",
                            "expected_value": "3"
                        }
                    ]
                },
                {
                    "exact_snippets": "high risk localized PCa (Gleason Grade Groups 4 and 5)",
                    "criterion": "Gleason Grade Group",
                    "requirements": [
                        {
                            "requirement_type": "grade group",
                            "expected_value": [
                                "4",
                                "5"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "localized PCa",
                    "criterion": "prostate cancer localization",
                    "requirements": [
                        {
                            "requirement_type": "localization",
                            "expected_value": "localized"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active urinary tract infection (UTI)",
            "criterions": [
                {
                    "exact_snippets": "Active urinary tract infection (UTI)",
                    "criterion": "urinary tract infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with Gleason Grade Group 1 or 2 PCa who select active surveillance as their cancer management method.",
            "criterions": [
                {
                    "exact_snippets": "Gleason Grade Group 1 or 2 PCa",
                    "criterion": "prostate cancer Gleason Grade Group",
                    "requirements": [
                        {
                            "requirement_type": "grade group",
                            "expected_value": [
                                "1",
                                "2"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "select active surveillance as their cancer management method",
                    "criterion": "cancer management method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "active surveillance"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to receive prostatic artery embolization (PAE) within 6-12 weeks of definitive radiation therapy",
            "criterions": [
                {
                    "exact_snippets": "Inability to receive prostatic artery embolization (PAE)",
                    "criterion": "ability to receive prostatic artery embolization (PAE)",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 6-12 weeks of definitive radiation therapy",
                    "criterion": "timing of prostatic artery embolization (PAE) relative to definitive radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prostate size greater than or equal to150 grams",
            "criterions": [
                {
                    "exact_snippets": "Prostate size greater than or equal to150 grams",
                    "criterion": "prostate size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "grams"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe allergic reaction to intravenous contrast media (iodinated and gadolinium- based) or any agents used during the PAE; patient cannot be medicated against allergic reaction prior to PAE.",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic reaction to intravenous contrast media (iodinated and gadolinium- based)",
                    "criterion": "severe allergic reaction to intravenous contrast media",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe allergic reaction to ... any agents used during the PAE",
                    "criterion": "severe allergic reaction to agents used during the PAE",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patient cannot be medicated against allergic reaction prior to PAE",
                    "criterion": "ability to be medicated against allergic reaction prior to PAE",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active cystolithiasis or prostatitis",
            "criterions": [
                {
                    "exact_snippets": "Active cystolithiasis",
                    "criterion": "cystolithiasis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active ... prostatitis",
                    "criterion": "prostatitis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior transurethral resection of the prostate (TURP) within 2 years",
            "criterions": [
                {
                    "exact_snippets": "Prior transurethral resection of the prostate (TURP) within 2 years",
                    "criterion": "transurethral resection of the prostate (TURP)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time_since_procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vulnerable subjects (e.g., inmates and developmentally delayed adults) who are subjects for whom the study may be unsafe or whose rights may be violated with enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Vulnerable subjects (e.g., inmates and developmentally delayed adults)",
                    "criterion": "vulnerable subject status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects for whom the study may be unsafe",
                    "criterion": "study safety for subject",
                    "requirements": [
                        {
                            "requirement_type": "safety",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects ... whose rights may be violated with enrollment",
                    "criterion": "risk of rights violation with enrollment",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}